Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK

200919 citationsReviewbronze Open Access

Authors

Jorge Arellano · Health Economics and Outcomes Research (United Kingdom)

Abstract

Atomoxetine is cost-effective and may have advantages over stimulants, including benefits to HRQL and no abuse liability and is the only treatment in the UK licensed for continued treatment into adulthood in adolescents who have shown a response from treatment.

Topics & Keywords

Attention Deficit Hyperactivity Disorder Pharmaceutical studies and practices

Publication Details

Published in: International Journal of Clinical Practice

Volume 63, Issue 7, pp. 1031-1040

DOI: 10.1111/j.1742-1241.2009.02090.x

Field-Weighted Citation Impact: 1.55

Command Palette

Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK

Authors

Abstract

Topics & Keywords

Publication Details